These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35590219)

  • 1. Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial.
    Kazierad DJ; Chidsey K; Somayaji VR; Bergman AJ; Birnbaum MJ; Calle RA
    Med; 2021 Jul; 2(7):800-813.e3. PubMed ID: 35590219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction.
    Gutierrez JA; Liu W; Perez S; Xing G; Sonnenberg G; Kou K; Blatnik M; Allen R; Weng Y; Vera NB; Chidsey K; Bergman A; Somayaji V; Crowley C; Clasquin MF; Nigam A; Fulham MA; Erion DM; Ross TT; Esler WP; Magee TV; Pfefferkorn JA; Bence KK; Birnbaum MJ; Tesz GJ
    Mol Metab; 2021 Jun; 48():101196. PubMed ID: 33667726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes.
    Saxena AR; Lyle SA; Khavandi K; Qiu R; Whitlock M; Esler WP; Kim AM
    Diabetes Obes Metab; 2023 Apr; 25(4):992-1001. PubMed ID: 36515213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis.
    Shepherd EL; Saborano R; Northall E; Matsuda K; Ogino H; Yashiro H; Pickens J; Feaver RE; Cole BK; Hoang SA; Lawson MJ; Olson M; Figler RA; Reardon JE; Nishigaki N; Wamhoff BR; Günther UL; Hirschfield G; Erion DM; Lalor PF
    JHEP Rep; 2021 Apr; 3(2):100217. PubMed ID: 33490936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fructose induced KHK-C can increase ER stress independent of its effect on lipogenesis to drive liver disease in diet-induced and genetic models of NAFLD.
    Park SH; Helsley RN; Fadhul T; Willoughby JLS; Noetzli L; Tu HC; Solheim MH; Fujisaka S; Pan H; Dreyfuss JM; Bons J; Rose J; King CD; Schilling B; Lusis AJ; Pan C; Gupta M; Kulkarni RN; Fitzgerald K; Kern PA; Divanovic S; Kahn CR; Softic S
    Metabolism; 2023 Aug; 145():155591. PubMed ID: 37230214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ketohexokinase-C regulates global protein acetylation to decrease carnitine palmitoyltransferase 1a-mediated fatty acid oxidation.
    Helsley RN; Park SH; Vekaria HJ; Sullivan PG; Conroy LR; Sun RC; Romero MDM; Herrero L; Bons J; King CD; Rose J; Meyer JG; Schilling B; Kahn CR; Softic S
    J Hepatol; 2023 Jul; 79(1):25-42. PubMed ID: 36822479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials.
    Calle RA; Amin NB; Carvajal-Gonzalez S; Ross TT; Bergman A; Aggarwal S; Crowley C; Rinaldi A; Mancuso J; Aggarwal N; Somayaji V; Inglot M; Tuthill TA; Kou K; Boucher M; Tesz G; Dullea R; Bence KK; Kim AM; Pfefferkorn JA; Esler WP
    Nat Med; 2021 Oct; 27(10):1836-1848. PubMed ID: 34635855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketohexokinase knockout mice, a model for essential fructosuria, exhibit altered fructose metabolism and are protected from diet-induced metabolic defects.
    Miller CO; Yang X; Lu K; Cao J; Herath K; Rosahl TW; Askew R; Pavlovic G; Zhou G; Li C; Akiyama TE
    Am J Physiol Endocrinol Metab; 2018 Sep; 315(3):E386-E393. PubMed ID: 29870677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.
    Cusi K; Alkhouri N; Harrison SA; Fouqueray P; Moller DE; Hallakou-Bozec S; Bolze S; Grouin JM; Jeannin Megnien S; Dubourg J; Ratziu V
    Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):889-902. PubMed ID: 34560015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials.
    Beysen C; Schroeder P; Wu E; Brevard J; Ribadeneira M; Lu W; Dole K; O'Reilly T; Morrow L; Hompesch M; Hellerstein MK; Li K; Johansson L; Kelly PF
    Diabetes Obes Metab; 2021 Mar; 23(3):700-710. PubMed ID: 33289350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of PF-06835919: A Potent Inhibitor of Ketohexokinase (KHK) for the Treatment of Metabolic Disorders Driven by the Overconsumption of Fructose.
    Futatsugi K; Smith AC; Tu M; Raymer B; Ahn K; Coffey SB; Dowling MS; Fernando DP; Gutierrez JA; Huard K; Jasti J; Kalgutkar AS; Knafels JD; Pandit J; Parris KD; Perez S; Pfefferkorn JA; Price DA; Ryder T; Shavnya A; Stock IA; Tsai AS; Tesz GJ; Thuma BA; Weng Y; Wisniewska HM; Xing G; Zhou J; Magee TV
    J Med Chem; 2020 Nov; 63(22):13546-13560. PubMed ID: 32910646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology.
    Amin NB; Saxena AR; Somayaji V; Dullea R
    Clin Ther; 2023 Jan; 45(1):55-70. PubMed ID: 36690550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fructose and hepatic insulin resistance.
    Softic S; Stanhope KL; Boucher J; Divanovic S; Lanaspa MA; Johnson RJ; Kahn CR
    Crit Rev Clin Lab Sci; 2020 Aug; 57(5):308-322. PubMed ID: 31935149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a Novel Ketohexokinase Inhibitor with Improved Drug Distribution in Target Tissue for the Treatment of Fructose Metabolic Disease.
    Zhu G; Li J; Lin X; Zhang Z; Hu T; Huo S; Li Y
    J Med Chem; 2023 Oct; 66(19):13501-13515. PubMed ID: 37766386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fructose consumption as a risk factor for non-alcoholic fatty liver disease.
    Ouyang X; Cirillo P; Sautin Y; McCall S; Bruchette JL; Diehl AM; Johnson RJ; Abdelmalek MF
    J Hepatol; 2008 Jun; 48(6):993-9. PubMed ID: 18395287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A luminescence-based protocol for assessing fructose metabolism via quantification of ketohexokinase enzymatic activity in mouse or human hepatocytes.
    Park SH; Helsley RN; Noetzli L; Tu HC; Wallenius K; O'Mahony G; Boucher J; Liu J; Softic S
    STAR Protoc; 2021 Sep; 2(3):100731. PubMed ID: 34409309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Sanyal A; Charles ED; Neuschwander-Tetri BA; Loomba R; Harrison SA; Abdelmalek MF; Lawitz EJ; Halegoua-DeMarzio D; Kundu S; Noviello S; Luo Y; Christian R
    Lancet; 2019 Dec; 392(10165):2705-2717. PubMed ID: 30554783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fructose Induced KHK-C Increases ER Stress and Modulates Hepatic Transcriptome to Drive Liver Disease in Diet-Induced and Genetic Models of NAFLD.
    Park SH; Helsley RN; Fadhul T; Willoughby JLS; Noetzli L; Tu HC; Solheim MH; Fujisaka S; Pan H; Dreyfuss JM; Bons J; Rose J; King CD; Schilling B; Lusis AJ; Pan C; Gupta M; Kulkarni RN; Fitzgerald K; Kern PA; Divanovic S; Kahn CR; Softic S
    bioRxiv; 2023 Jan; ():. PubMed ID: 36747758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fructose as a key player in the development of fatty liver disease.
    Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
    World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.